Literature DB >> 6741802

Differences in hemodynamic response to vasodilation due to calcium channel antagonism with nifedipine and direct-acting agonism with hydralazine in chronic refractory congestive heart failure.

U Elkayam, L Weber, C R McKay, S H Rahimtoola.   

Abstract

The hemodynamic response to a similar reduction of systemic vascular resistance after nifedipine and hydralazine administration was compared in a randomized crossover protocol in patients with severe chronic congestive heart failure (CHF). All 15 patients showed a 25% or greater reduction in vascular resistance with intravenous hydralazine (5 to 30 mg) and 11 patients showed a similar response with oral nifedipine (20 to 50 mg). In the latter 11 patients, despite similar reductions in systemic vascular resistance (35 +/- 2% with nifedipine and 36 +/- 4% with hydralazine, difference not significant), nifedipine resulted in a smaller increase in stroke volume index (from 23 +/- 2 to 30 +/- 2 ml/m2 and from 24 +/- 2 to 34 +/- 2 ml/m2 with hydralazine, p less than 0.05), cardiac index (from 2.0 +/- 0.1 to 2.6 +/- 0.2 liters/min/m2 with nifedipine and from 2.0 +/- 0.1 to 2.8 +/- 0.2 liters/min/m2 with hydralazine, p less than 0.05) and stroke work index (from 25 +/- 3 to 27 +/- 3 gm/m2 with nifedipine and from 26 +/- 2 to 32 +/- 2 gm/m2 with hydralazine, p less than 0.05). The decrease in blood pressure after nifedipine was slightly but not significantly larger than that with hydralazine (13 +/- 3% vs 8 +/- 2%). The changes in right atrial pressure, pulmonary artery wedge pressure and pulmonary vascular resistance were similar. The 4 patients who did not reduce their systemic vascular resistance by at least 25% with nifedipine had a worsening of their hemodynamic state as evidenced by 1 or more of the following findings: elevation of vascular resistance, decrease in cardiac index and increase in pulmonary artery wedge pressure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6741802     DOI: 10.1016/0002-9149(84)90316-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 2.  Calcium antagonists in patients with heart failure. A review.

Authors:  H Reicher-Reiss; E Barasch
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  The treatment of heart failure. A methodological review of the literature.

Authors:  G H Guyatt
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

4.  Comparison of haemodynamic effects of nifedipine and molsidomine in patients with coronary artery disease.

Authors:  M Kyriakidis; G Vyssoulis; P Sfikakis; C Kyriakidis; C Pitsavos; K Valsamis; V Nomikos; P Toutouzas
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure.

Authors:  L Dei Cas; M Metra; R Ferrari; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

6.  Improvement of relaxation velocity parameters by calcium channel blockers in the aging rabbit myocardium.

Authors:  N C Morcos; J M Gardin; N Tomita; W L Henry
Journal:  Basic Res Cardiol       Date:  1992 Sep-Oct       Impact factor: 17.165

Review 7.  The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review.

Authors:  A L Soward; G L Vanhaleweyk; P W Serruys
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.